Clinical Trials Logo

Epithelial Tumor clinical trials

View clinical trials related to Epithelial Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05165433 Recruiting - Metastatic Cancer Clinical Trials

Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

FORTIFY
Start date: April 13, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.

NCT ID: NCT05043714 Recruiting - Metastatic Cancer Clinical Trials

Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours

NEBULA
Start date: December 1, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours. The purpose is to characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or advanced epithelial tumours

NCT ID: NCT04053283 Recruiting - Metastatic Cancer Clinical Trials

First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector

STAR
Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.